Strategic Licence and Partnership for Greater China Market
Filed with ASX · · 3 pages · English
Telix Pharmaceuticals Limited on 6ix
In the deck
Earlier from Telix Pharmaceuticals
- App 4C and Activities Report for September 2020 Quarter
- FDA grants Orphan Drug Designation for glioma imaging agent
- Telix submits NDA to US FDA for Prostate Cancer Imaging
- Strategic Collaboration with Varian for Prostate Imaging
- IRE Distribution Partnership for Prostate Cancer Imaging
Later from Telix Pharmaceuticals
- Investor Briefing - Asia Strategy
- NDA for Prostate Cancer Imaging accepted by US FDA
- Prostate Cancer Therapy FDA Meeting Update
- Telix Acquires TheraPharm GmbH
- Acquisition of TheraPharm GmbH - Investor Call
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals